Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations

The study will also include patients who because of COVID had undergone up to 3 months neoadjuvant hormonal therapy before surgery for clinical T1/T2 BC.

Inclusion Criteria:

Age older than 18
Pre- or post-menopausal women with Stage I-III breast cancer
Status post neoadjuvant systemic therapy
Status post-chemotherapy breast surgery
Original biopsy-proven invasive breast cancer, excised with negative margins of at least 1 mm (patients with focally positive margin are not excluded).
Status post segmental mastectomy or mastectomy, with either negative sentinel node biopsy and/or axillary node dissection (at least 6 nodes removed).
Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document

Exclusion Criteria:

Previous radiation therapy to the ipsilateral breast and/or nodal area
Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy
Pregnant or lactating women
Concurrent chemotherapy, with the exception of anti HER2neu therapies
Inadequate axillary dissection in a setting of positive sentinel node
Patients with more than 5 nodes involved at axillary dissection will be excluded from this study since they will be eligible to receive radiotherapy to level I and II axilla.